Clinical trial · Observational

Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia

Genetic Risk Classes in Adult Acute Lymphocytic Leukemia

NCT00898261CI-TRIAL-00027691completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at gene expression in tissue from patients with acute lymphoblastic leukemia enrolled in clinical trial ECOG-2993.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Leukemia	Leukemia	ONTOLOGY_EXACT	0.90

Interventions

Interventions (3)

Intervention	Type	Mapped drug	Match
flow cytometry	Other	—	UNRESOLVED
microarray analysis	Genetic	—	UNRESOLVED
reverse transcriptase-polymerase chain reaction	Genetic	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (3)

measure
Genes involved in specific biologic processes or molecular functions that contribute to the mechanisms by which the BCR/ABL tyrosine kinase induces a leukemic phenotype
timeFrame
1 month
measure
Comparison of patterns of mRNA expression of BCR/ABL fusion protein in patients with B-lineage acute lymphoblastic leukemia (ALL) vs patients with ALL who lack cytogenetic abnormalities
timeFrame
1 month
measure
Shared and differing expression patterns in patients with BCR/ABL-positive and cytogenetically negative ALL with respect to achievement of complete remission and duration of disease-free and overall survival
timeFrame
1 month

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 15 Years
Maximum age: 65 Years

Show eligibility criteria text

DISEASE CHARACTERISTICS:

* Confirmed diagnosis of acute lymphoblastic leukemia
* Tissue banked on protocol ECOG-2993 meeting the following criteria:

  * Leukemic blast cell population immunophenotyped in detail (e.g., including CD25) in ECOG's Immunophenotyping Reference Laboratory
  * Flow cytometric analysis of gated blast cells reveals association with the B-cell lineage
  * Mononuclear cell fraction used for RNA isolation contains 75-99% blasts (median 85%)
  * Negative for TEL/AML1, MLL/AF4, and E2A/PBX1 by qualitative reverse transcription-polymerase chain reaction (RT-PCR)
  * No FLT3 gene mutations
  * BCR/ABL-positive samples meeting the following criteria:

    * Presence of t(9;22)(q34;q11) by standard cytogenetics
    * Detection of either p190 BCR/ABL or p210 BCR/ABL transcripts by qualitative RT-PCR
  * Patients with genetic risk factors must meet the following criterion:

    * Only a normal diploid karyotype is present in ≥ 15 metaphases by standard cytogenetics

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

References

Publications (0)

Data not yet available

No reference posted for this study.